Canaccord starts Palvella Therapeutics with a Buy on lead programs’ potential
As previously reported, Canaccord analyst Whitney Ijem initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $39 price ...
GlobalData on MSN1 天
Supernus’s stock sinks after depression drug fails trial
Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...
Health Check: Brokers slash Cochlear valuations as customers hold tight on product upgrades
Today’s burning question from Cochlear's (ASX:COH) poorly received interim results is whether users are on a buyer’s strike ahead of upgraded implants and processors – or whether the problems are more ...
Monthly Prescribing Reference6 天
Encapsulated Rapamycin Fast Tracked for Familial Adenomatous Polyposis
The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.